First human test of new blood disorder drug shows early safety profile
NCT ID NCT06294275
Summary
This was an early-stage study to check the safety and see how the body handles a new drug called LP-001. It involved 68 healthy volunteers and tested single and multiple doses. The main goal was to see what side effects might occur and to measure how long the drug stays in the bloodstream.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Public Health Clinical Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.